行情

CCXI

CCXI

ChemoCentryx
NASDAQ

实时行情|Nasdaq Last Sale

7.58
-0.06
-0.79%
盘前: 7.60 +0.02 +0.26% 09:00 09/16 EDT
开盘
7.67
昨收
7.64
最高
7.85
最低
7.32
成交量
52.24万
成交额
--
52周最高
14.98
52周最低
6.16
市值
4.42亿
市盈率(TTM)
-8.2499
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CCXI 新闻

  • 美官员散布“华为威胁”,华春莹:该防思科和苹果
  • 环球网.4小时前
  • 本周开庭!苹果拟对抗欧盟140亿美元天价税单
  • 新浪科技.5小时前
  • 沪指震荡微跌 沙特石油设施遇袭、油价一度跳升20%
  • 新浪财经.5小时前
  • 沙特阿美据称仍在推进IPO工作 尽管设施受到重创
  • 新浪财经综合.5小时前

更多

所属板块

制药
-0.54%
制药与医学研究
-0.38%

热门股票

名称
价格
涨跌幅

CCXI 简况

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).
展开

Webull提供ChemoCentryx Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。